Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 43 min ago
Peer-reviewedCC BYDiagnostics (Basel, Switzerland)

Is Eligibility Enough? Pretreatment Prediction of Failure to Reach a Second Cycle of [177Lu]Lu-PSMA Radioligand Therapy

  • Halim Özçevik1
  • Enes Mustafa Kaya2
  • Burcu Esen Akkaş2
  • Gündüzalp Buğrahan Babacan2
  • Ayşe Betül Dere2
  • Berke Güner2
  • Hatice Pekediş2
  • Cengiz Yağmur2
  • Meryem Kaya2
  1. 1, 06800 Ankara, Türkiye
  2. 2Department of Nuclear Medicine, Başakşehir Çam and Sakura City Hospital, 34480 Istanbul, Türkiye; (E.M.K.); (B.E.A.); (G.B.B.); (A.B.D.); (B.G.); (H.P.); (C.Y.); (M.K.)
Read full textPDFCite

Related

  1. Development and internal validation of a pretreatment magnetic resonance imaging-based radiomics prediction model for 1-year overall survival in treatment-naïve patients with hepatocellular carcinoma receiving transarterial chemoembolization combined with targeted therapy and immune checkpoint inhibitors.
    Chengyi Jiang, Shuai Zhang, Beiguang Zhang +6
    Journal of gastrointestinal oncologyPeer-reviewedCC BY-NC-NDFull textMedical imaging & radiologyEurope PMC
  2. Targeted radioligand therapy in oncology: clinical development across targets and platforms
    Jiaxin An, Xiaolei Meng, Lara Hathout +5
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textMedical imaging & radiologyCrossref
  3. Treatment Sequencing in ARPI-Pre-Exposed Metastatic Castration-Resistant Prostate Cancer: Radioligand Therapy, PARP Inhibitors, and Antibody-Drug Conjugates.
    Baha Sharaf, Mohammad Al-Rwashdeh, Osama El Khatib +6
    CancersPeer-reviewedCC BYFull textOncologyEurope PMC
  4. Beyond Phenylbutyric Acid: Evans Blue and Ibuprofen as Albumin- Binding Motifs for PSMA-Targeted Radioligand Therapy of Prostate Cancer
    Cyril Fersing, Johanne Vanney, Jade Torchio +2
    Current Topics in Medicinal ChemistryPeer-reviewedCC BY 4.0Full text1 citedSystems & synthetic biologyInorganic & organometallic chemistryHAL
  5. Organ and tumor dosimetry of [161Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC
    Andrea Schaefer-Schuler, Arne Blickle, Sebastian Ganz +8
    European Journal of Nuclear Medicine and Molecular ImagingPeer-reviewedCC BY 4.0Full textMedical imaging & radiologyPMC

Cite

BibTeXRIS
BibTeX
@article{ozcevik2026eligibility,
  title = {{Is Eligibility Enough? Pretreatment Prediction of Failure to Reach a Second Cycle of [177Lu]Lu-PSMA Radioligand Therapy}},
  author = {Halim Özçevik and Enes Mustafa Kaya and Burcu Esen Akkaş and Gündüzalp Buğrahan Babacan and Ayşe Betül Dere and Berke Güner and Hatice Pekediş and Cengiz Yağmur and Meryem Kaya},
  journal = {Diagnostics (Basel, Switzerland)},
  year = {2026},
  month = oct,
  url = {https://europepmc.org/article/PMC/PMC13702933},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Is Eligibility Enough? Pretreatment Prediction of Failure to Reach a Second Cycle of [177Lu]Lu-PSMA Radioligand Therapy
AU  - Halim Özçevik
AU  - Enes Mustafa Kaya
AU  - Burcu Esen Akkaş
AU  - Gündüzalp Buğrahan Babacan
AU  - Ayşe Betül Dere
AU  - Berke Güner
AU  - Hatice Pekediş
AU  - Cengiz Yağmur
AU  - Meryem Kaya
PY  - 2026
DA  - 2026/10/01
JO  - Diagnostics (Basel, Switzerland)
UR  - https://europepmc.org/article/PMC/PMC13702933
SN  - 2075-4418
ER  -